Glycocalyx as Possible Limiting Factor in COVID-19.

Wadowski, Patricia P; Jilma, Bernd; Kopp, Christoph W; Ertl, Sebastian; Gremmel, Thomas; Koppensteiner, Renate

Wadowski, Patricia P; Jilma, Bernd; Kopp, Christoph W; Ertl, Sebastian; Gremmel, Thomas; Koppensteiner, Renate.

Wadowski PP; Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Jilma B; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Kopp CW; Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Ertl S; Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Gremmel T; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Koppensteiner R; Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Front Immunol ; 12: 607306, 2021.

Article in English | MEDLINE | ID: covidwho-1127982

Subject(s)

COVID-19/virology; Glycocalyx/virology; SARS-CoV-2/pathogenicity; COVID-19/metabolism; COVID-19/pathology; Endothelium/pathology; Endothelium/virology; Glycocalyx/metabolism; Glycocalyx/pathology; Heparitin Sulfate/metabolism; Humans

Keywords

COVID-19; SARS-CoV-2; complement; glycocalyx; heparan sulfate

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Glycocalyx / SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.607306

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google